Gain-of-Function, Paused: The 2025 Executive Order That Halted the Research — and the Policy Vacuum It Left Behind

Executive Order 14292 did what a lot of people wanted after COVID: it froze federal funding for "dangerous gain-of-function" research. It also tore up the old oversight rules before the new ones existed — and the deadlines to replace them came and went. NU lays out the actual order, the actual gap, and why "we paused it" and "nobody's minding the store" are both true right now. Receipts, not verdicts.

1. The order, on the record

On May 5, 2025, the President signed Executive Order 14292, "Improving the Safety and Security of Biological Research." It did three concrete things【1】【2】:

• Immediately paused new federal funding for research meeting its definition of "dangerous gain-of-function research."
• Rescinded the 2024 U.S. Government oversight policy for Dual Use Research of Concern (DURC) and pandemic-pathogen research (P3CO).
• Gave the Office of Science and Technology Policy (OSTP) a set of deadlines (90 / 120 / 180 days) to write a replacement policy【1】【3】.

The order's definition is specific: research on an infectious agent or toxin that enhances its pathogenicity or increases its transmissibility【2】. That's the actual line — worth knowing, because "gain-of-function" gets thrown around loosely, and the EO draws a narrower box than the internet does.

2. Why a lot of people cheered — and weren't wrong to

After COVID, the argument for a pause isn't fringe. The lab-leak hypothesis moved from "conspiracy" to an official leading candidate in U.S. government reviews, and the oversight of taxpayer-funded high-risk pathogen work — including the EcoHealth/Wuhan funding — was documented as inadequate. Against that backdrop, "stop funding the most dangerous experiments until we fix the rules" is a defensible, even mainstream, position. NU won't pretend the pause is irrational; it answers a real, documented failure.

The scientific-governance world took it seriously too: a peer-reviewed mSphere analysis called it a "possible turning point for research governance in the life sciences," not a stunt【4】.

3. The part that's a genuine problem: the vacuum

Here's the honest other side, and it's not small. The EO rescinded the old rules immediately but the replacement never landed on schedule. Per the tracking record, the 90-, 120-, and 180-day deadlines have all passed, and research flagged as potential "dangerous gain-of-function" remains paused until NIH issues specific implementation requirements【1】【5】.

The result is what biosafety professionals call a policy vacuum: the old oversight framework is gone, the new one isn't finalized, and institutions are operating under uncertainty【4】. That cuts against the whole point. The goal was better oversight — but for now there's a stretch where the formal DURC/P3CO structure has been removed and not yet replaced. "We made it safer" and "we left a gap" are, at this moment, both true.

NU's read: a pause you don't replace on time isn't the same as reform. The EO is the easy 80%; the replacement policy is the hard 20% that actually determines whether biosecurity improved or just got more ad hoc.

4. What to watch (the real receipts)

This story is settled by documents, not vibes. The ones that decide it:

• NIH Guide Notice NOT-OD-26-101 — "USG Policy for Stopping High-Risk Life Sciences Research," the implementation mechanism【5】.
• OSTP's replacement policy — whether and when it finalizes, and how narrow/broad its final definition is.
• The Congressional Research Service product (IN12554) — Congress's own neutral summary of the executive actions【3】.

When those land, you can grade the outcome. Until then, anyone claiming this either "ended dangerous research forever" or "changed nothing" is ahead of the paperwork.

5. NU's bottom line

• EO 14292 (May 5, 2025) paused federal funding for dangerous gain-of-function research and scrapped the 2024 oversight rules.
• The pause answers a real, documented post-COVID failure — cheering it isn't unreasonable.
• But the replacement policy missed its deadlines, leaving a biosecurity governance vacuum — the reform is only half-built.
• The verdict lives in NIH/OSTP implementation documents that haven't fully landed. Read those, linked below, before you score it.

Not policy advice — analysis of the public record. The primary documents are linked; judge the record yourself.

Sources

1. CASRAI — Executive Order 14292, "Improving the Safety and Security of Biological Research" (signed May 5, 2025; paused funding; rescinded 2024 DURC/P3CO policy; OSTP deadlines) — casrai.org/news/executive-order-14292-biological-research-security
2. AAMC — White House issues executive order restricting gain-of-function and other research (definition + provisions) — aamc.org/advocacy-policy/washington-highlights/white-house-issues-executive-order-restricting-gain-function-and-other-research
3. Congress.gov (CRS product IN12554) — Recent Executive Actions Related to Gain-of-Function Research and Laboratory Biosafety — congress.gov/crs-product/IN12554
4. mSphere (ASM) — "A possible turning point for research governance in the life sciences" (peer-reviewed analysis; policy-vacuum concern) — journals.asm.org/doi/full/10.1128/msphere.00407-25
5. NIH Guide — NOT-OD-26-101: USG Policy for Stopping High-Risk Life Sciences Research (implementation; deadlines passed, research remains paused) — grants.nih.gov/grants/guide/notice-files/NOT-OD-26-101.html

NU original — commentary and analysis of the public record, "kooky till proven." NOT policy or legal advice. The executive order, its definitions, and its implementation status are documented in the linked primary sources; the "policy vacuum" characterization comes from biosafety-governance analysts. Read the primary documents and judge for yourself.